Current and future directions for dendritic cell vaccines

Published: 23 March 2020
Interview
Gerard Bos
Gerard Bos
GERARD BOS was born in Wageningen, The Netherlands. After Medical School and a PhD program on immunology (both at the medical school in Maastricht) Gerard Bos started training in internal medicine in Maastricht and The Hague. After training for internal medicine he was trained as a Hematologist followed with a fellowship at the Daniel den Hoed Cancer Centre, Rotterdam, for 3 years (head Professor Dr B Lowenberg). Thereafter he obtained a fellowship (Clinical Research Award by the Dutch Cancer Foundation) to perform a 2-year research program on tumor-immunology (Leiden, Brussels and Utrecht). He started in Maastricht 2000, as internist-hematologist. His extra focus is on M. myeloma and chronic myeloid leukemia. Preclinical research has a focus on cell therapy: development of cancer vaccines, the role of natural killer cells in the fight against cancer and immune reconstitution after bone marrow transplantation. Under this topic special attention is present for a possible role for vitamin C in immune reconstitution. In 2013, he was appointed a professor of medical education and tumor-immunology. In 2016, he was appointed a professor of immunology of cancer. Since 2015 he has been CEO of CiMaas, a biotech company with a focus on immunotherapy.

GERARD BOS was born in Wageningen, The Netherlands. After Medical School and a PhD program on immunology (both at the medical school in Maastricht) Gerard Bos started training in internal medicine in Maastricht and The Hague. After training for internal medicine he was trained as a Hematologist followed with a fellowship at the Daniel den Hoed Cancer Centre, Rotterdam, for 3 years (head Professor Dr B Lowenberg). Thereafter he obtained a fellowship (Clinical Research Award by the Dutch Cancer Foundation) to perform a 2-year research program on tumor-immunology (Leiden, Brussels and Utrecht). He started in Maastricht 2000, as internist-hematologist. His extra focus is on M. myeloma and chronic myeloid leukemia. Preclinical research has a focus on cell therapy: development of cancer vaccines, the role of natural killer cells in the fight against cancer and immune reconstitution after bone marrow transplantation. Under this topic special attention is present for a possible role for vitamin C in immune reconstitution. In 2013, he was appointed a professor of medical education and tumor-immunology. In 2016, he was appointed a professor of immunology of cancer. Since 2015 he has been CEO of CiMaas, a biotech company with a focus on immunotherapy.

Read now